Roquefort Therapeutics (LSE:ROQ) EV-to-EBIT : -2.24 (As of May. 23, 2025)

Roquefort Therapeutics EV-to-EBIT Chart

Competitive Comparison of Roquefort Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Roquefort Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roquefort Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's EV-to-EBIT falls into.

Roquefort Therapeutics EV-to-EBIT Calculation

Roquefort Therapeutics's EV-to-EBIT for today is calculated as:

Roquefort Therapeutics's current Enterprise Value is £2.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roquefort Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was £-1.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roquefort Therapeutics  (LSE:ROQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Roquefort Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Roquefort Therapeutics's Enterprise Value for the quarter that ended in Dec. 2024 was £5.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roquefort Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was £-1.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roquefort Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description